Invivyd, Inc.
Invivyd is a biopharmaceutical company dedicated to delivering protection from serious viral infectious diseases through innovative antibody-based therapies. They leverage state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering to develop a robust pipeline of product candidates for diseases such as COVID-19 and influenza. Their mission focuses on protecting vulnerable populations from evolving viral threats with a platform approach that combines scientific innovation and strategic partnerships.
Industries
Nr. of Employees
medium (51-250)
Invivyd, Inc.
Waltham, Massachusetts, United States, North America
Products
Extended–half‑life monoclonal antibody authorized for pre‑exposure prophylaxis of COVID‑19 (pemivibart)
A monoclonal antibody product developed for pre‑exposure prophylaxis of COVID‑19; received emergency use authorization from the U.S. FDA in March 2024 (authorization limited to the EUA declaration period).
Extended–half‑life monoclonal antibody authorized for pre‑exposure prophylaxis of COVID‑19 (pemivibart)
A monoclonal antibody product developed for pre‑exposure prophylaxis of COVID‑19; received emergency use authorization from the U.S. FDA in March 2024 (authorization limited to the EUA declaration period).
Services
Patient support program for benefits, access, and reimbursement
Program offering benefits investigations, access and reimbursement assistance, treatment coordination, and payor advocacy for patients and caregivers using company products.
Research and development collaboration services
Collaborative research partnerships with academic institutions, medical centers, and biopharma companies to leverage the company’s platform for antibody discovery and engineering.
Patient support program for benefits, access, and reimbursement
Program offering benefits investigations, access and reimbursement assistance, treatment coordination, and payor advocacy for patients and caregivers using company products.
Research and development collaboration services
Collaborative research partnerships with academic institutions, medical centers, and biopharma companies to leverage the company’s platform for antibody discovery and engineering.
Expertise Areas
- Monoclonal antibody discovery and engineering
- Viral surveillance and predictive evolution modeling
- Clinical trial management (Phase 1–3)
- Regulatory affairs for biologics (including EUA processes)
Key Technologies
- Deep B-cell mining
- Antibody engineering and affinity maturation
- Predictive viral evolution modeling
- In vitro neutralization assays